Subcutaneous delivery allows structured dosing and reproducible receptor engagement assessment
Wardenaar FC, Ceelen IJ, Van Dijk JW, Hangelbroek RW, Van Roy L, Van der Pouw B, De Vries JH, Mensink M, Witkamp RF
Thus, the inability to account for inhibition of IGF-2 binding to the IGF-1R is an important limitation in this study, which should be considered when assessing outcomes from human trials using IGF-1R mAbs
Many people notice improved sleep within the first couple of weeks, followed by better recovery and energy over the first month or two
This synergy is the pharmacological foundation for combining either GHRP with a GHRH analog like CJC-1295
So which one should you pick